<DOC>
	<DOCNO>NCT01481220</DOCNO>
	<brief_summary>Patients Myelodysplastic Syndromes ( MDS ) often suffer low platelet level may lead bleed complication . Treatment cytotoxic agent decrease platelet level . Eltrombopag relatively new drug increase platelet level blood work directly bone marrow . It available treatment disease Immunological Thrombocytopenic Purpura ( ITP ) . In study patient MDS low platelet level treat cytotoxic agent Azacitidine also receive Eltrombopag . The administration Eltrombopag MDS patient treat Azacitidine may result less dose reduction less treatment delay Azacitidine may reduce need thrombocyte transfusion low risk bleed complication . This phase I study , mean major goal investigate safety tolerability Eltrombopag patient group . It also generate basis phase II-III-study .</brief_summary>
	<brief_title>Safety Study Eltrombopag Combined With Azacitidine Treat Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Adult subject ( 18 year age old ) advance MDS sAML/MDS require treatment Azacitidine approve EMEA : MDS classify Intermediate 2risk high risk accord international prognostic scoring system ( IPSS ) Chronic myelomonocytic leukaemia ( CMML ) 1029 % bone marrow blast without myeloproliferative disease Acute myeloblastic leukaemia ( AML ) 2030 % bone marrow blast multilineage dysplasia accord WHO classification . 2 . Platelet count &lt; 75 x 109 /L start Azacitidine treatment . 3 . Subjects must platelet count platelet transfusion data available period 4 week prior inclusion . 4 . During 8 week prior inclusion study , subject must baseline bone marrow examination include follow : cytomorphology confirm bone marrow blast cytogenetics 5 . ECOG Status 02 . 6 . Subject able understand comply protocol requirement instruction . 7 . Subject sign date informed consent . 8 . Adequate baseline organ function define criterion : total bilirubin ( except Gilbert 's Syndrome ) &lt; /= 1.5xULN ALT AST &lt; /= 3xULN creatinine &lt; /= 2.5 xULN 9 . Subject practice acceptable method contraception ( documented CRF ) .Female subject ( female partner male subject ) must either non childbearing potential ( hysterectomy , bilateral oophorectomy , bilateral tubal ligation postmenopausal &gt; 1 year ) , childbearing potential use 1 follow highly effective method contraception ( i.e. , Pearl Index &lt; 1.0 % ) 2 week prior administration study medication , throughout study , 28 day completion premature discontinuation study : Complete abstinence intercourse ; Intrauterine device ( IUD ) ; Two form barrier contraception ( diaphragm plus spermicide , male condom plus spermicide ) ; Male partner sterile prior entry study partner female ; Systemic contraceptive ( combine progesterone ) . Exclusion criterion : 1 . Subjects diagnosis acute promyelocytic leukemia . 2 . Patients short life expectancy ( le 3 month ) 3 . Patients bone marrow fibrosis allow bone marrow aspiration ( socalled `` dry tap '' ) fibrosis grade II III ( grade accord European consensus grade bone marrow fibrosis . 4 . History treatment cancer MDS sAML/MDS systemic chemotherapy and/or radiotherapy within last 2 year . 5 . Patients clinically significant splenomegaly , &gt; 16 cm spleen length measure ultrasound 6 . Patients know liver cirrhosis 7 . Patients East Asian ancestry Chinese , Japanese , Taiwanese Korean . 8 . History treatment romiplostim TPOR agonists . 9. subject QTc &gt; 450 msec ( QTc &gt; 480 msec subject Bundle Branch Block ) . 10 . Subjects know thrombophilic risk factor . Exception : Subjects potential benefit participate study outweigh potential risk thromboembolic event , determine investigator . 11 . Female subject nurse pregnant ( positive serum urine Betahuman chorionic gonadotropin [ BhCG ] pregnancy test ) screen predose Day 1 . 12 . Current alcohol drug abuse . 13 . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication . 14 . Active uncontrolled infection . 15 . Subjects infect Hepatitis B , C Human Immunodeficiency Virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>azacitidine</keyword>
	<keyword>Eltrombopag</keyword>
	<keyword>Thrombopoietin-receptor agonist</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Transfusion dependency</keyword>
	<keyword>Safety study</keyword>
</DOC>